Doliver Capital Advisors LP bought a new position in AbbVie Inc. (NYSE:ABBV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,687 shares of the company’s stock, valued at approximately $775,000.

Other institutional investors have also recently made changes to their positions in the company. Formidable Asset Management LLC grew its stake in shares of AbbVie by 0.3% during the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock worth $285,000 after acquiring an additional 10 shares during the last quarter. WealthTrust Axiom LLC grew its stake in shares of AbbVie by 0.3% during the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after acquiring an additional 15 shares during the last quarter. Abner Herrman & Brock LLC grew its stake in shares of AbbVie by 0.3% during the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after acquiring an additional 18 shares during the last quarter. Bollard Group LLC grew its stake in shares of AbbVie by 0.5% during the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after acquiring an additional 19 shares during the last quarter. Finally, St. Louis Trust Co grew its stake in shares of AbbVie by 0.7% during the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock worth $248,000 after acquiring an additional 23 shares during the last quarter. Institutional investors and hedge funds own 69.32% of the company’s stock.

Shares of AbbVie Inc. (NYSE ABBV) opened at $95.95 on Friday. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie Inc. has a 52-week low of $59.27 and a 52-week high of $98.52. The company has a market capitalization of $153,177.45, a P/E ratio of 18.07, a price-to-earnings-growth ratio of 1.33 and a beta of 1.52.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. During the same quarter in the prior year, the firm posted $1.21 EPS. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. sell-side analysts forecast that AbbVie Inc. will post 5.55 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.96%. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is currently 62.29%.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered AbbVie from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. ValuEngine lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 1st. BMO Capital Markets set a $84.00 target price on AbbVie and gave the company a “hold” rating in a research report on Monday, December 4th. BidaskClub upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 11th. Finally, Leerink Swann set a $106.00 target price on AbbVie and gave the company a “buy” rating in a research report on Tuesday, December 5th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $97.96.

In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the transaction, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at approximately $7,915,276.98. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 277,125 shares of company stock worth $25,891,756. Insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Doliver Capital Advisors LP Invests $775,000 in AbbVie Inc. (ABBV) Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/doliver-capital-advisors-lp-invests-775000-in-abbvie-inc-abbv-stock/1755278.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.